Biallelic truncating variants in MAPKAPK5 cause a new developmental disorder involving neurological, cardiac, and facial anomalies combined with synpolydactyly

Abstract

Purpose

This study aimed to identify the genetic cause of a new multiple congenital anomalies syndrome observed in three individuals from two unrelated families.

Methods

Clinical assessment was conducted prenatally and at different postnatal stages. Genetic studies included exome sequencing (ES) combined with single-nucleotide polymorphism (SNP) array based homozygosity mapping and trio ES. Dermal fibroblasts were used for functional assays.

Results

A clinically recognizable syndrome characterized by severe developmental delay, variable brain anomalies, congenital heart defects, dysmorphic facial features, and a distinctive type of synpolydactyly with an additional hypoplastic digit between the fourth and fifth digits of hands and/or feet was identified. Additional features included eye abnormalities, hearing impairment, and electroencephalogram anomalies. ES detected different homozygous truncating variants in MAPKAPK5 in both families. Patient-derived cells showed no expression of MAPKAPK5 protein isoforms and reduced levels of the MAPKAPK5-interacting protein ERK3. F-actin recovery after latrunculin B treatment was found to be less efficient in patient-derived fibroblasts than in control cells, supporting a role of MAPKAPK5 in F-actin polymerization.

Conclusion

Our data indicate that loss-of-function variants in MAPKAPK5 result in a severe developmental disorder and reveal a major role of this gene in human brain, heart, and limb development.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Clinical features of individuals with biallelic pathogenic variants in MAPKAPK5.
Fig. 2: Description of the variants identified in MAPKAPK5 and their effect on MK5 and ERK3 expression.
Fig. 3: Loss of MK5 impairs F-actin cytoskeleton recovery.
Fig. 4: F-actin/G-actin quantification in primary fibroblasts.

Data availability

Data supporting this paper are contained within the article and Supplementary information. Any additional data not compromised by ethical issues will be available upon request.

References

  1. 1.

    Plotnikov, A., Zehorai, E., Procaccia, S. & Seger, R. The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim. Biophys. Acta 1813, 1619–1633 (2011).

    CAS  Article  Google Scholar 

  2. 2.

    Cargnello, M. & Roux, P. P. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol. Mol. Biol. Rev. 75, 50–83 (2011).

    CAS  Article  Google Scholar 

  3. 3.

    Ni, H., Wang, X. S., Diener, K. & Yao, Z. MAPKAPK5, a novel mitogen-activated protein kinase (MAPK)-activated protein kinase, is a substrate of the extracellular-regulated kinase (ERK) and p38 kinase. Biochem. Biophys. Res. Commun. 243, 492–496 (1998).

    CAS  Article  Google Scholar 

  4. 4.

    Seternes, O. M. et al. Both binding and activation of p38 mitogen-activated protein kinase (MAPK) play essential roles in regulation of the nucleocytoplasmic distribution of MAPK-activated protein kinase 5 by cellular stress. Mol. Cell. Biol. 22, 6931–6945 (2002).

    CAS  Article  Google Scholar 

  5. 5.

    New, L., Jiang, Y. & Han, J. Regulation of PRAK subcellular location by p38 MAP kinases. Mol. Biol. Cell. 14, 2603–2616 (2003).

    CAS  Article  Google Scholar 

  6. 6.

    New, L. et al. PRAK, a novel protein kinase regulated by the p38 MAP kinase. EMBO J. 17, 3372–3384 (1998).

    CAS  Article  Google Scholar 

  7. 7.

    Aberg, E. et al. Regulation of MAPK-activated protein kinase 5 activity and subcellular localization by the atypical MAPK ERK4/MAPK4. J. Biol. Chem. 281, 35499–35510 (2006).

    CAS  Article  Google Scholar 

  8. 8.

    Kant, S. et al. Characterization of the atypical MAPK ERK4 and its activation of the MAPK-activated protein kinase MK5. J. Biol. Chem. 281, 35511–35519 (2006).

    CAS  Article  Google Scholar 

  9. 9.

    Schumacher, S. et al. Scaffolding by ERK3 regulates MK5 in development. EMBO J. 23, 4770–4779 (2004).

    CAS  Article  Google Scholar 

  10. 10.

    Seternes, O. M. et al. Activation of MK5/PRAK by the atypical MAP kinase ERK3 defines a novel signal transduction pathway. EMBO J. 23, 4780–4791 (2004).

    CAS  Article  Google Scholar 

  11. 11.

    Deleris, P. et al. Activation loop phosphorylation of ERK3/ERK4 by group I p21-activated kinases (PAKs) defines a novel PAK-ERK3/4-MAPK-activated protein kinase 5 signaling pathway. J. Biol. Chem. 286, 6470–6478 (2011).

    CAS  Article  Google Scholar 

  12. 12.

    Estan, M. C. et al. Recessive mutations in muscle-specific isoforms of FXR1 cause congenital multi-minicore myopathy. Nat. Commun. 10, 797 (2019).

    CAS  Article  Google Scholar 

  13. 13.

    Holtgrewe, M., et al. VarFish: comprehensive DNA variant analysis for diagnostics and research. Nucl. Acids Res. https://doi.org/10.1093/nar/gkaa241 (2020).

  14. 14.

    Ehmke, N. et al. Biallelic variants in KYNU cause a multisystemic syndrome with hand hyperphalangism. Bone. 133, 115219 (2020).

    CAS  Article  Google Scholar 

  15. 15.

    Kosmas, K. et al. CAP2 is a regulator of the actin cytoskeleton and its absence changes infiltration of inflammatory cells and contraction of wounds. Eur. J. Cell. Biol. 94, 32–45 (2015).

    CAS  Article  Google Scholar 

  16. 16.

    Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 581, 434–443 (2020).

    CAS  Article  Google Scholar 

  17. 17.

    Nagy, E. & Maquat, L. E. A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance. Trends Biochem. Sci. 23, 198–199 (1998).

    CAS  Article  Google Scholar 

  18. 18.

    Ronkina, N. et al. Comparative analysis of two gene-targeting approaches challenges the tumor-suppressive role of the protein kinase MK5/PRAK. PLoS One 10, e0136138 (2015).

    Article  Google Scholar 

  19. 19.

    Tak, H. et al. 14-3-3epsilon inhibits MK5-mediated cell migration by disrupting F-actin polymerization. Cell. Signal. 19, 2379–2387 (2007).

    CAS  Article  Google Scholar 

  20. 20.

    Shi, Y. et al. Elimination of protein kinase MK5/PRAK activity by targeted homologous recombination. Mol. Cell. Biol. 23, 7732–7741 (2003).

    CAS  Article  Google Scholar 

  21. 21.

    Sun, P. et al. PRAK is essential for ras-induced senescence and tumor suppression. Cell. 128, 295–308 (2007).

    CAS  Article  Google Scholar 

  22. 22.

    Brand, F. et al. The extracellular signal-regulated kinase 3 (mitogen-activated protein kinase 6 [MAPK6])-MAPK-activated protein kinase 5 signaling complex regulates septin function and dendrite morphology. Mol. Cell. Biol. 32, 2467–2478 (2012).

    CAS  Article  Google Scholar 

  23. 23.

    Svitkina, T. The actin cytoskeleton and actin-based motility. Cold Spring Harb. Perspect. Biol. 10, a018267 (2018).

  24. 24.

    Fischer, M., Kaech, S., Knutti, D. & Matus, A. Rapid actin-based plasticity in dendritic spines. Neuron. 20, 847–854 (1998).

    CAS  Article  Google Scholar 

  25. 25.

    Nawaito, S. A. et al. MK5 haplodeficiency attenuates hypertrophy and preserves diastolic function during remodeling induced by chronic pressure overload in the mouse heart. Am. J. Physiol. Heart Circ. Physiol. 313, H46–H58 (2017).

    Article  Google Scholar 

  26. 26.

    Nawaito, S. A. et al. MK5 haplodeficiency decreases collagen deposition and scar size during post-myocardial infarction wound repair. Am. J. Physiol. Heart Circ. Physiol. 316, H1281–H1296 (2019).

    CAS  Article  Google Scholar 

  27. 27.

    Chen, G., Hitomi, M., Han, J. & Stacey, D. W. The p38 pathway provides negative feedback for Ras proliferative signaling. J. Biol. Chem. 275, 38973–38980 (2000).

    CAS  Article  Google Scholar 

  28. 28.

    Yoshizuka, N. et al. PRAK suppresses oncogenic ras-induced hematopoietic cancer development by antagonizing the JNK pathway. Mol. Cancer Res. 10, 810–820 (2012).

    CAS  Article  Google Scholar 

  29. 29.

    Tajan, M., Paccoud, R., Branka, S., Edouard, T. & Yart, A. The RASopathy family: consequences of germline activation of the RAS/MAPK pathway. Endocr. Rev. 39, 676–700 (2018).

    Article  Google Scholar 

  30. 30.

    Sobreira, N., Schiettecatte, F., Valle, D. & Hamosh, A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum. Mutat. 36, 928–930 (2015).

    Article  Google Scholar 

  31. 31.

    Moens, U. & Kostenko, S. Structure and function of MK5/PRAK: the loner among the mitogen-activated protein kinase-activated protein kinases. Biol. Chem. 394, 1115–1132 (2013).

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We are grateful to patients and their parents for their participation in this study. The work at IIB was financially supported by the Spanish Ministry of Science, Innovation and Universities (PID2019-105620RB-I00/AEI/10.13039/501100011033 and SAF2016‐75434‐R (AEI/FEDER, UE). The authors also acknowledge the GeneMatcher tool30 which allowed the identification of these two families and Manuel Holtgrewe, Core Unit Bioinformatics of the Berlin Institute of Health (BIH), for processing of the exome data of family 2.

Author information

Affiliations

Authors

Contributions

Conceptualization: D.H., F.B., S.T., G.A.O., M.A., P.L., V.L.R.-P. Funding acquisition: V.L.R.-P. Formal analysis: E.F.-N., A.R.-B., N.E. Investigation: E.F.-N., R.G.-C., A.R.-B., J.N., V.L.R.-P., N.E., F.B. Project administration: P.L., V.L.R.-P. Resources: D.H., F.B., M.A., S.T., G.A.O., S.S. Supervision: D.H., F.B., S.T., M.A., V.L.R.-P. Visualization: E.F.-N., A.R.-B., G.A.O., M.A., D.H., F.B., V.L.R.-P. Writing—original draft: D.H., F.B., M.A., S.T., G.A.O., P.L., V.L.R.-P. Writing—review & editing: D.H., S.S., N.E., F.B., E.F.-N., A.R.-B., P.L., G.A.O., S.T., M.A., V.L.R.-P.

Corresponding authors

Correspondence to Denise Horn or Victor L. Ruiz-Perez.

Ethics declarations

Ethics Declaration

Parental consent was obtained for all clinical and molecular studies of this report and for the publication of clinical photographs. All studies and investigations were performed according to the declaration of Helsinki principles of medical research involving human subjects and the study was approved by institutional Ethics Committees of National Research Centre, Hospital La Paz-CSIC and Charité-Universitaetsmedizin (EA2/140/17).

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Horn, D., Fernández-Núñez, E., Gomez-Carmona, R. et al. Biallelic truncating variants in MAPKAPK5 cause a new developmental disorder involving neurological, cardiac, and facial anomalies combined with synpolydactyly. Genet Med (2021). https://doi.org/10.1038/s41436-020-01052-2

Download citation

Search

Quick links